Interaction between Chronic Stress and Obesity in Pancreatic Cancer Progression
慢性压力和肥胖在胰腺癌进展中的相互作用
基本信息
- 批准号:10612088
- 负责人:
- 金额:$ 17.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdrenergic AgentsAdrenergic beta-AntagonistsAmygdaloid structureApplications GrantsCaloriesCancer EtiologyCardiovascular DiseasesCatecholaminesCell ProliferationCessation of lifeChemopreventionChemopreventive AgentChronicChronic stressClinicalCollaborationsComplexDevelopmentDietDisease ProgressionEnvironmental Risk FactorEventFDA approvedFatty acid glycerol estersFunctional disorderGenesGenetic ModelsGrowthHematologic NeoplasmsHigh Fat DietHigh PrevalenceHormonesHumanInsulin ReceptorInsulin ResistanceKRAS2 geneKRASG12DKnowledgeLesionLinkMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMalignant neoplasm of pancreasMediatingMetabolicMetabolic syndromeMolecularMusMutateMutationNeurobiologyNeuronsNeurotransmittersNon-Insulin-Dependent Diabetes MellitusObesityOncogenesOutcomeOutcome StudyPancreatic Ductal AdenocarcinomaPancreatic Intraepithelial NeoplasiaPathway interactionsPharmaceutical PreparationsPreventionReceptor SignalingResearchRiskSignal PathwaySignal TransductionSocial isolationSolidSolid NeoplasmStimulantStressSurvival RateSystemWestern WorldWorkbeta-adrenergic receptordiet-induced obesitydietary controlepidemiology studyexperimental studyhuman diseaseislet stem cellsmouse modelneuropeptide Ynovelnovel strategiespancreas developmentpancreatic cancer cellspancreatic cancer modelpancreatic cell linepancreatic ductal adenocarcinoma cellpre-clinicalpreclinical studypreventresponsestressorsynergismtherapeutic developmenttumortumor progressionvirtual
项目摘要
ABSTRACT
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human diseases, with overall 5-year
survival rate of only 9%. PDAC is estimated to become the 2nd leading cause of cancer-related deaths in the
US within the next decade. Virtually all PDACs involve activating mutations in the KRAS oncogene, which are
thought to represent an initiating event. Although mutated Kras is necessary for PDAC initiation it is not
sufficient for the rapid progression of the disease. In addition to mutation in tumor suppressive genes that
collaborate with mutated Kras, there is increasing recognition of the importance of environmental factors in
PDAC progression. In this context, many epidemiological studies have linked obesity with increased risk for
developing PDAC and other clinically aggressive cancers. Preclinical studies using the conditional KrasG12D
mouse model (KC), demonstrated that KC mice subjected to high fat calorie diet became obese and displayed
a marked increase in PanIN lesions and invasive PDAC. There is also evidence that chronic stress accelerates
the progression of a variety of tumor types, including PDAC through β-adrenergic signaling. Recent studies
identified a complex neurobiological interaction between chronic stress, diet-induced obesity (DIO) and insulin
resistance. The objective of this proposal is to explore critical gaps in current knowledge concerning the
interaction between stress and diet-induced obesity on PDAC progression. Specifically, we propose to
examine the impact of different chronic stressors on the development of PDAC using a genetically modified
mouse model that recapitulates key features of the human disease. Mechanistic studies in PDAC cells will
elucidate the molecular mechanisms that mediate the growth-promoting effects of stress neurotransmitters,
including crosstalk between β-adrenergic receptors and insulin receptor signaling pathways leading to PDAC
cell proliferation. Our central hypothesis proposed is that interaction between chronic stress and diet-induced
obesity potently accelerates the progression of Kras-initiated precursor lesions to invasive PDAC in KC mice.
To explore this hypothesis and elucidate the molecular mechanism(s) involved, we propose two Specific Aims:
1) Determine the development of PanINs and PDAC using the conditional KrasG12D mouse model subjected to
chronic stressors in combination with diet-induced obesity (DIO) and define the chemopreventive effects of β-
adrenergic receptor blocking in each condition. 2) Determine the molecular pathways implicated in
catecholamine-induced PDAC cell proliferation using human and mouse pancreatic cell lines and identify
crosstalk mechanisms between β-adrenergic receptor and insulin receptor signaling systems. The
identification that chronic stress interacting with DIO is a potent stimulant of PDAC progression as well as the
elucidation of the signaling mechanisms that drive PDAC development in response to stress and DIO, as
proposed in this application, will be of major translational significance to discover novel targets and drugs for
PDAC prevention.
摘要
胰腺导管腺癌(Pdac)是人类最致命的疾病之一,总病死率为5年。
存活率只有9%。据估计,PDAC将成为全球癌症相关死亡的第二大原因
在接下来的十年里。几乎所有的PDAC都涉及激活KRAS癌基因的突变,这些突变是
被认为代表启蒙事件的。虽然突变的Kras是启动PDAC所必需的,但它不是
足以应对疾病的快速发展。除了肿瘤抑制基因突变外,
与突变的Kras合作,人们越来越多地认识到环境因素在
PDAC进展。在这种背景下,许多流行病学研究已经将肥胖与增加的风险联系在一起
发展成PDAC和其他临床侵袭性癌症。使用条件性KrasG12D的临床前研究
小鼠模型(KC),高脂饮食导致KC小鼠肥胖并表现为
PAIN病变和侵袭性PDAC明显增加。也有证据表明,慢性压力会加速
多种肿瘤类型的进展,包括通过β-肾上腺素能信号传导的动脉导管未闭。最新研究
发现慢性应激、饮食诱导肥胖(DIO)和胰岛素之间存在复杂的神经生物学相互作用
抵抗。这项建议的目标是探索当前知识中关于
压力和饮食诱导的肥胖在PDAC进展中的交互作用。具体来说,我们建议
用基因修饰的方法检测不同慢性应激源对PDAC发展的影响
概括人类疾病主要特征的小鼠模型。PDAC细胞的机制研究将
阐明应激神经递质促进生长作用的分子机制,
包括β-肾上腺素能受体和胰岛素受体信号通路之间的串扰
细胞增殖。我们提出的中心假设是慢性压力和饮食诱导之间的相互作用
肥胖有效地加速了Kras启动的前体病变向KC小鼠侵袭性PDAC的进展。
为了探索这一假说并阐明其中的分子机制(S),我们提出了两个具体目标:
1)使用条件性KrasG12D小鼠模型确定Panins和PDAC的发育
慢性应激源与饮食诱导的肥胖相结合,并确定β的化学预防作用-
肾上腺素能受体在每种情况下都被阻断。2)确定所涉及的分子途径
儿茶酚胺诱导人和小鼠胰腺细胞系PDAC细胞增殖及鉴定
β-肾上腺素能受体和胰岛素受体信号系统之间的串扰机制。这个
发现慢性应激与DIO的相互作用是PDAC进展的有力刺激因素,以及
阐明驱动PDAC发展的信号机制,以响应应激和DIO,AS
在这项申请中提出的,将对发现新的靶点和药物具有重大的翻译意义
PDAC预防。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Statins Inhibit Inflammatory Cytokine Production by Macrophages and Acinar-to-Ductal Metaplasia of Pancreatic Cells.
他汀类药物抑制巨噬细胞的炎症细胞因子产生,胰腺细胞的腺泡到导管化生。
- DOI:10.1016/j.gastha.2022.04.012
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Ako, Soichiro;Teper, Yaroslav;Ye, Linda;Sinnett-Smith, James;Hines, Oscar J;Rozengurt, Enrique;Eibl, Guido
- 通讯作者:Eibl, Guido
Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice.
- DOI:10.1038/s41598-023-43498-9
- 发表时间:2023-09-26
- 期刊:
- 影响因子:4.6
- 作者:Teper, Yaroslav;Ye, Linda;Waldron, Richard T.;Lugea, Aurelia;Sun, Xiaoying;Sinnett-Smith, James;Hines, Oscar J.;Pandol, Stephen J.;Rozengurt, Enrique;Eibl, Guido
- 通讯作者:Eibl, Guido
Statins inhibit protein kinase D (PKD) activation in intestinal cells and prevent PKD1-induced growth of murine enteroids.
他汀类药物可抑制肠细胞中蛋白激酶 D (PKD) 的激活,并阻止 PKD1 诱导的小鼠肠样细胞的生长。
- DOI:10.1152/ajpcell.00286.2022
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Sinnett-Smith,James;Torres-Marquez,MEugenia;Chang,Jen-Kuan;Shimizu,Yuki;Hao,Fang;Martin,MartinG;Rozengurt,Enrique
- 通讯作者:Rozengurt,Enrique
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Guido Erwin Michael Eibl其他文献
Guido Erwin Michael Eibl的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Guido Erwin Michael Eibl', 18)}}的其他基金
Interaction between Chronic Stress and Obesity in Pancreatic Cancer Progression
慢性压力和肥胖在胰腺癌进展中的相互作用
- 批准号:
10409304 - 财政年份:2022
- 资助金额:
$ 17.87万 - 项目类别:
Chemoprevention and mechanisms of obesity-promoted pancreatic adenocarcinoma
肥胖促进的胰腺癌的化学预防和机制
- 批准号:
10398844 - 财政年份:2020
- 资助金额:
$ 17.87万 - 项目类别:
Chemoprevention and mechanisms of obesity-promoted pancreatic adenocarcinoma
肥胖促进的胰腺癌的化学预防和机制
- 批准号:
10605224 - 财政年份:2020
- 资助金额:
$ 17.87万 - 项目类别:
Project 1: Adipose tissue inflammation in obesity-promoted pancreatic cancer
项目1:肥胖促进的胰腺癌中的脂肪组织炎症
- 批准号:
10398845 - 财政年份:2020
- 资助金额:
$ 17.87万 - 项目类别:
Project 1: Adipose tissue inflammation in obesity-promoted pancreatic cancer
项目1:肥胖促进的胰腺癌中的脂肪组织炎症
- 批准号:
10605225 - 财政年份:2020
- 资助金额:
$ 17.87万 - 项目类别:
Inflammatory processes In diet-Induced pancreatic cancer promotion
饮食诱发的胰腺癌促进中的炎症过程
- 批准号:
8561427 - 财政年份:2013
- 资助金额:
$ 17.87万 - 项目类别:
Targeting diet-induced promotion of Kras-initiated pancreatic adenocarcinoma
针对饮食诱导的 Kras 引发的胰腺癌的促进作用
- 批准号:
8337028 - 财政年份:2012
- 资助金额:
$ 17.87万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 17.87万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 17.87万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 17.87万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 17.87万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 17.87万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 17.87万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 17.87万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 17.87万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 17.87万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 17.87万 - 项目类别: